Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
PAC1
MCID: SPP011
MIFTS: 60

Suppression of Tumorigenicity 12 (PAC1)

Categories: Cancer diseases, Reproductive diseases
Genes Variations Tissues Related diseases Publications Pathways
Sources

Aliases & Classifications for Suppression of Tumorigenicity 12

About this section

MalaCards integrated aliases for Suppression of Tumorigenicity 12:

Name: Suppression of Tumorigenicity 12 57
Prostate Adenocarcinoma 57 12 13 15
Adenocarcinoma of Prostate 6 73
Prostate Adenocarcinoma 1; Pac1 57
Prostate Adenocarcinoma 1 57
St12 57
Pac1 57

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Reproductive diseases
See all MalaCards categories (disease lists)


External Ids:

OMIM 57 601188
Disease Ontology 12 DOID:2526
NCIt 50 C2919
UMLS 73 C0007112
Sources

Summaries for Suppression of Tumorigenicity 12

About this section
Disease Ontology : 12 A prostate carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Suppression of Tumorigenicity 12, also known as prostate adenocarcinoma, is related to adenocarcinoma and prostatic acinar adenocarcinoma. An important gene associated with Suppression of Tumorigenicity 12 is CTNNB1 (Catenin Beta 1), and among its related pathways/superpathways are Human cytomegalovirus infection and PI3K-Akt signaling pathway. Affiliated tissues include prostate, bone and lymph node, and related phenotypes are Decreased viability in esophageal squamous lineage and Decreased cell migration

Description from OMIM: 601188
Sources

Related Diseases for Suppression of Tumorigenicity 12

About this section

Diseases related to Suppression of Tumorigenicity 12 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 253)
# Related Disease Score Top Affiliating Genes
1 adenocarcinoma 32.2 AKT1 BRAF CTNNB1 HRAS PIK3CA PTEN
2 prostatic acinar adenocarcinoma 32.2 AMACR KLK3 NKX3-1 TMPRSS2
3 prostatic hyperplasia, benign 30.7 AR FOLH1 KLK3
4 transitional cell carcinoma 30.6 BRAF HRAS PTEN TP53
5 adenoma 30.6 BRAF CTNNB1 SMAD4 TP53
6 small cell carcinoma 30.6 CHGA KLK3 PTEN TP53
7 nephrogenic adenoma 30.6 AMACR KLK3 NKX3-1
8 myeloma, multiple 30.5 AKT1 BRAF HRAS IDH1 TP53
9 small cell cancer of the lung 30.3 AKT1 CHGA PIK3CA PTEN TP53
10 bladder urothelial carcinoma 30.2 AKT1 AR BRAF CTNNB1 HRAS IDH1
11 squamous cell carcinoma 30.2 AKT1 BRAF CTNNB1 GSTP1 HRAS PIK3CA
12 prostate cancer 30.2 AKT1 AMACR AR CHGA CTNNB1 FOLH1
13 lung cancer 30.1 AKT1 BRAF CHGA GSTP1 HRAS PIK3CA
14 carcinosarcoma 30.1 CTNNB1 HRAS PIK3CA PTEN TP53
15 sarcoma 30.1 BRAF CTNNB1 HRAS PIK3CA TP53
16 breast adenocarcinoma 30.1 AKT1 PIK3CA PTEN SMAD4 TP53
17 gastrointestinal stromal tumor 30.1 AKT1 BRAF CHGA PTEN TP53
18 adenoid cystic carcinoma 30.0 AKT1 CTNNB1 HRAS IDH1 PIK3CA PTEN
19 squamous cell carcinoma, head and neck 29.9 AKT1 BRAF CTNNB1 GSTP1 HRAS PIK3CA
20 lymphoepithelioma-like acinar prostate adenocarcinoma 12.1
21 prostate colloid adenocarcinoma 11.7
22 prostate signet ring cell adenocarcinoma 11.1
23 adult hepatocellular carcinoma 10.4 CTNNB1 PIK3CA TP53
24 rare adenocarcinoma of the breast 10.4 AKT1 PIK3CA TP53
25 prostate transitional cell carcinoma 10.4 CTNNB1 KLK3 PIK3CA
26 submandibular gland cancer 10.4 TP53 KLK3
27 prostate adenoid cystic carcinoma 10.4 HRAS KLK3 PIK3CA
28 female reproductive endometrioid cancer 10.4 CTNNB1 PTEN TP53
29 thyroid hurthle cell adenoma 10.4 PIK3CA PTEN
30 spitz nevus 10.4 BRAF HRAS TP53
31 anal squamous cell carcinoma 10.4 AKT1 PIK3CA TP53
32 ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3 10.4 PIK3CA PTEN TP53
33 nevus of ota 10.4 BRAF TP53
34 proteus syndrome 10.4 AKT1 PIK3CA PTEN
35 serous cystadenocarcinoma 10.4 AKT1 HRAS PIK3CA TP53
36 cystadenocarcinoma 10.4 AKT1 HRAS PIK3CA TP53
37 gliomatosis cerebri 10.4 IDH1 PTEN TP53
38 prostate squamous cell carcinoma 10.4 HRAS KLK3 TP53
39 leopard syndrome 10.4 AKT1 BRAF HRAS
40 intestinal benign neoplasm 10.4 TP53 HRAS CTNNB1
41 female urethral cancer 10.4 CHGA KLK3
42 ovary adenocarcinoma 10.4 TP53 PIK3CA HRAS
43 malignant ovarian surface epithelial-stromal neoplasm 10.4 AKT1 HRAS PIK3CA TP53
44 skin squamous cell carcinoma 10.4 TP53 PIK3CA HRAS
45 ovarian clear cell carcinoma 10.4 TP53 PTEN PIK3CA
46 biliary tract neoplasm 10.4 HRAS SMAD4 TP53
47 ovary epithelial cancer 10.4 AKT1 HRAS PIK3CA TP53
48 nasopharyngeal disease 10.4 TP53 CTNNB1 AKT1
49 nodular prostate 10.4 AR FOLH1 KLK3
50 congenital lipomatous overgrowth, vascular malformations, and epidermal nevi 10.4 SMAD4 PIK3CA AKT1

Graphical network of the top 20 diseases related to Suppression of Tumorigenicity 12:



Diseases related to Suppression of Tumorigenicity 12
Sources

Symptoms & Phenotypes for Suppression of Tumorigenicity 12

About this section

Clinical features from OMIM:

601188

GenomeRNAi Phenotypes related to Suppression of Tumorigenicity 12 according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in esophageal squamous lineage GR00235-A 9.93 BRAF CHGA CTNNB1 HRAS IDH1 KLK3
2 Decreased cell migration GR00055-A-1 9.72 AKT1 BRAF CTNNB1 HRAS PIK3CA
3 Increased cell death HMECs cells GR00103-A-0 9.43 CTNNB1 GSTP1 KLK3 PIK3CA PTEN TP53
4 Decreased sensitivity to paclitaxel GR00112-A-0 9.26 PTEN SMAD4
5 Increased cell migration GR00055-A-3 8.92 BRAF CTNNB1 HRAS PIK3CA

MGI Mouse Phenotypes related to Suppression of Tumorigenicity 12:

46 (show all 23)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.42 AKT1 AMACR AR BRAF CHGA CTNNB1
2 growth/size/body region MP:0005378 10.4 AKT1 AMACR AR BRAF CHGA CTNNB1
3 mortality/aging MP:0010768 10.4 AKT1 AMACR AR BRAF CHGA CTNNB1
4 endocrine/exocrine gland MP:0005379 10.38 AKT1 AR BRAF CHGA CTNNB1 HRAS
5 behavior/neurological MP:0005386 10.35 AKT1 AR BRAF CTNNB1 HRAS NKX3-1
6 cardiovascular system MP:0005385 10.34 AKT1 AR BRAF CHGA CTNNB1 HRAS
7 cellular MP:0005384 10.33 AKT1 AR BRAF CTNNB1 KLF6 NKX3-1
8 embryo MP:0005380 10.32 AKT1 AR BRAF CTNNB1 KLF6 NKX3-1
9 integument MP:0010771 10.24 AKT1 AR BRAF CTNNB1 HRAS KLF6
10 neoplasm MP:0002006 10.2 AKT1 AR BRAF CTNNB1 HRAS NKX3-1
11 digestive/alimentary MP:0005381 10.19 AR BRAF CTNNB1 HRAS NKX3-1 PTEN
12 nervous system MP:0003631 10.17 AKT1 AR BRAF CHGA CTNNB1 HRAS
13 adipose tissue MP:0005375 10.16 AKT1 AMACR AR BRAF PIK3CA PTEN
14 liver/biliary system MP:0005370 10.16 AKT1 AMACR AR BRAF CTNNB1 KLF6
15 muscle MP:0005369 10.13 AKT1 AR BRAF CHGA CTNNB1 PIK3CA
16 limbs/digits/tail MP:0005371 10.07 AR BRAF CTNNB1 NKX3-1 PTEN SMAD4
17 normal MP:0002873 10.02 AKT1 AR BRAF CTNNB1 HRAS PTEN
18 no phenotypic analysis MP:0003012 9.95 CHGA CTNNB1 HRAS NKX3-1 PIK3CA SRRM4
19 reproductive system MP:0005389 9.93 AKT1 AR BRAF CHGA CTNNB1 KLF6
20 renal/urinary system MP:0005367 9.86 AR BRAF CHGA CTNNB1 HRAS PTEN
21 pigmentation MP:0001186 9.72 AR BRAF CTNNB1 PTEN TP53
22 respiratory system MP:0005388 9.61 AKT1 BRAF CTNNB1 HRAS IDH1 PTEN
23 skeleton MP:0005390 9.36 AKT1 AR BRAF CTNNB1 HRAS IDH1
Sources

Drugs & Therapeutics for Suppression of Tumorigenicity 12

About this section

Search Clinical Trials , NIH Clinical Center for Suppression of Tumorigenicity 12

Sources

Genetic Tests for Suppression of Tumorigenicity 12

About this section
Sources

Anatomical Context for Suppression of Tumorigenicity 12

About this section

MalaCards organs/tissues related to Suppression of Tumorigenicity 12:

41
Prostate, Bone, Lymph Node, Brain, Lung, Myeloid, Colon
Sources

Publications for Suppression of Tumorigenicity 12

About this section

Articles related to Suppression of Tumorigenicity 12:

(show top 50) (show all 634)
# Title Authors Year
1
Prostate adenocarcinoma in a young patient with multiple endocrine neoplasia 2B. ( 29530270 )
2018
2
Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study. ( 29976500 )
2018
3
Transformation of Prostate Adenocarcinoma Into Small-Cell Neuroendocrine Cancer Under Androgen Deprivation Therapy: Much Is Achieved But More Information Is Needed. ( 30557524 )
2018
4
Asynchronous tumour quadruplicity: rectosigmoid adenocarcinoma, renal cell carcinoma, prostate adenocarcinoma and neuroendocrine small-cell lung cancer - a case report. ( 30470124 )
2018
5
Comparison of hock- and footpad-injection as a prostate adenocarcinoma model in rats. ( 30400793 )
2018
6
Distinct Imaging Characteristics of Different Metastases From Primary Prostate Adenocarcinoma and Rectal Carcinoid Tumor on 18F-Fluciclovine and 68Ga-DOTATATE PET/CT. ( 30371597 )
2018
7
Solitary Mucinous Prostate Adenocarcinoma Lung Metastasis Detected by 68Ga-PSMA-11 PET/CT. ( 30293922 )
2018
8
An efficient MRI agent targeting extracellular markers in prostate adenocarcinoma. ( 30257047 )
2018
9
68Ga-PSMA-11 PET/CT in Newly Diagnosed Prostate Adenocarcinoma. ( 30273204 )
2018
10
The U Shape of Prostate-specific Antigen and Prostate Cancer-specific Mortality in High-grade Metastatic Prostate Adenocarcinoma. ( 30217630 )
2018
11
Prognostic value and potential function of splicing events in prostate adenocarcinoma. ( 30221674 )
2018
12
Analysis of competing endogenous RNA network to identify the key RNAs associated with prostate adenocarcinoma. ( 30195637 )
2018
13
Is oxidative stress measured by thiol/disulphide homeostasis status associated with prostate adenocarcinoma? ( 30135630 )
2018
14
Small Cell Transformation of Metastatic Prostate Adenocarcinoma Diagnosed by Dual Tracer PET/CT (68Ga-PSMA and 18F-FDG): Potential Clinical Utility in Therapeutic Decision-Making and Treatment Monitoring. ( 30139889 )
2018
15
Nontoxic Glucomoringin-Isothiocyanate (GMG-ITC) Rich Soluble Extract Induces Apoptosis and Inhibits Proliferation of Human Prostate Adenocarcinoma Cells (PC-3). ( 30150582 )
2018
16
Immune Checkpoint-Mediated Interactions Between Cancer and Immune Cells in Prostate Adenocarcinoma and Melanoma. ( 30108594 )
2018
17
Prostate-Specific Antigen (PSA) Bounce After Dose-Escalated External Beam Radiation Therapy Is an Independent Predictor of PSA Recurrence, Metastasis, and Survival in Prostate Adenocarcinoma Patients. ( 29254782 )
2018
18
The expression of p-mTOR and COUP-TFII correlates with increased lymphangiogenesis and lymph node metastasis in prostate adenocarcinoma. ( 29544697 )
2018
19
Synchronous Bone Metastasis From Multiple Myeloma and Prostate Adenocarcinoma as Initial Presentation of Coexistent Malignancies. ( 29761076 )
2018
20
Quantification of the heterogeneity of cytokeratin 18 immunoexpression in prostate adenocarcinoma and normal prostate: Global and local features. ( 29863745 )
2018
21
Testicular Metastasis in Prostate Adenocarcinoma: a Rare and Incidental Diagnosis on Histopathology. ( 29887721 )
2018
22
AKR1C3 Inhibitor KV-37 Exhibits Antineoplastic Effects and Potentiates Enzalutamide in Combination Therapy in Prostate Adenocarcinoma Cells. ( 29891491 )
2018
23
An Interleukin-6 Single Nucleotide Polymorphism and Susceptibility to Prostate Adenocarcinoma and Bone Metastasis in an Iranian Population ( 29938471 )
2018
24
Comprehensive molecular classification of localized prostate adenocarcinoma reveals a tumour subtype predictive of non-aggressive disease. ( 29945238 )
2018
25
Can Early Dynamic Positron Emission Tomography/Computed Tomography Obviate the Need for Postdiuresis Image in 68Ga-PSMA-HBED-CC Scan for Evaluation of Prostate Adenocarcinoma? ( 29962715 )
2018
26
Role of co-expression of estrogen receptor beta and Ki67 in prostate adenocarcinoma. ( 29984337 )
2018
27
Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. ( 29992241 )
2018
28
Coexisting prostate adenocarcinoma with multiple myeloma: A rare case report. ( 30004075 )
2018
29
Prostate-specific antigen doubling time is a significant predictor of overall and disease-free survival in patients with prostate adenocarcinoma treated with brachytherapy. ( 30061057 )
2018
30
δ-Tocopherol inhibits the development of prostate adenocarcinoma in prostate specific Pten-/- mice. ( 29121168 )
2018
31
Gastrointestinal Bleeding from Metastatic Prostate Adenocarcinoma to the Stomach. ( 28377935 )
2017
32
An Assessment of Early Response to Targeted Therapy via Molecular Imaging: A Pilot Study of 3'-deoxy-3'[(18)F]-Fluorothymidine Positron Emission Tomography (18)F-FLT PET/CT in Prostate Adenocarcinoma. ( 28375169 )
2017
33
Overexpression of Aquaporin-1 is a Prognostic Factor for Biochemical Recurrence in Prostate Adenocarcinoma. ( 27817002 )
2017
34
Clinical significance of endothelial cell marker CD34 and mast cell marker CD117 in prostate adenocarcinoma. ( 28552539 )
2017
35
Risk of lymph node metastases in pathological gleason scorea8o6 prostate adenocarcinoma: Analysis of institutional and population-based databases. ( 27692833 )
2017
36
Complete biochemical response after pulmonary metastasectomy in prostate adenocarcinoma. ( 28932626 )
2017
37
The Development of Prostate Adenocarcinoma in a Transgender Male to Female Patient: Could Estrogen Therapy Have Played a Role? ( 28191651 )
2017
38
Metastatic Prostate Adenocarcinoma to the Brain: Case Reports and Literature Review. ( 28352499 )
2017
39
Incidental Prostate Adenocarcinoma in Cystoprostatectomy Specimens: Partial Versus Complete Prostate Sampling. ( 28381150 )
2017
40
Macrophage type 2 differentiation in a patient with laryngeal squamous cell carcinoma and metastatic prostate adenocarcinoma to the cervical lymph nodes. ( 28716144 )
2017
41
Endoplasmic reticulum protein ERp46 in prostate adenocarcinoma. ( 28521463 )
2017
42
Dishevelled segment polarity protein 3 (DVL3): a novel and easily applicable recurrence predictor in localised prostate adenocarcinoma. ( 28107606 )
2017
43
Epididymal metastasis from prostate adenocarcinoma: An unusual and challenging diagnosis suspected in gallium-68 prostate-specific membrane antigen-positron emission tomography/computed tomography and histologically confirmed. ( 28216940 )
2017
44
Ductal variant of prostate adenocarcinoma harbor Xenotropic murine leukemia virus related virus (XMRV) infection: a novel finding in subtype of prostate cancer. ( 28861296 )
2017
45
Incomplete cavernous sinus syndrome as the initial manifestation of a previously undetected metastatic prostate adenocarcinoma. ( 28474478 )
2017
46
Differentiating tumor heterogeneity in formalin-fixed paraffin-embedded (FFPE) prostate adenocarcinoma tissues using principal component analysis of matrix-assisted laser desorption/ionization imaging mass spectral data. ( 27791282 )
2017
47
Performance of different prostate specific antibodies in the cytological diagnosis of metastatic prostate adenocarcinoma. ( 28888085 )
2017
48
Prostate adenocarcinoma metastases to the testis and brain: case report and review of the literature. ( 28845236 )
2017
49
Molecular classification of prostate adenocarcinoma by the integrated somatic mutation profiles and molecular network. ( 28389666 )
2017
50
Modeling African American prostate adenocarcinoma by inducing defined genetic alterations in organoids. ( 28881646 )
2017
Sources

Variations for Suppression of Tumorigenicity 12

About this section

ClinVar genetic disease variations for Suppression of Tumorigenicity 12:

6 (show top 50) (show all 374)
# Gene Variation Type Significance SNP ID Assembly Location
1 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 GRCh37 Chromosome 10, 89692905: 89692905
2 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 GRCh38 Chromosome 10, 87933148: 87933148
3 SMAD4 NM_005359.5(SMAD4): c.1157G> A (p.Gly386Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912580 GRCh37 Chromosome 18, 48593406: 48593406
4 SMAD4 NM_005359.5(SMAD4): c.1157G> A (p.Gly386Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912580 GRCh38 Chromosome 18, 51067036: 51067036
5 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
6 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh38 Chromosome 17, 7674221: 7674221
7 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
8 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230
9 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh37 Chromosome 17, 7577547: 7577547
10 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh38 Chromosome 17, 7674229: 7674229
11 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
12 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh38 Chromosome 17, 7674220: 7674220
13 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Conflicting interpretations of pathogenicity rs28934574 GRCh37 Chromosome 17, 7577094: 7577094
14 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Conflicting interpretations of pathogenicity rs28934574 GRCh38 Chromosome 17, 7673776: 7673776
15 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
16 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230
17 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
18 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh38 Chromosome 17, 7673802: 7673802
19 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
20 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 GRCh38 Chromosome 17, 7674872: 7674872
21 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
22 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
23 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
24 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh38 Chromosome 11, 534288: 534288
25 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
26 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
27 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
28 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
29 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
30 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
31 PIK3CA NM_006218.3(PIK3CA): c.1636C> G (p.Gln546Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
32 PIK3CA NM_006218.3(PIK3CA): c.1636C> G (p.Gln546Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh38 Chromosome 3, 179218306: 179218306
33 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
34 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh38 Chromosome 3, 179218303: 179218303
35 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 NCBI36 Chromosome 3, 180418785: 180418785
36 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
37 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
38 PIK3CA NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
39 PIK3CA NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh38 Chromosome 3, 179218306: 179218306
40 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
41 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
42 BRAF NM_004333.4(BRAF): c.1801A> G (p.Lys601Glu) single nucleotide variant Pathogenic rs121913364 GRCh37 Chromosome 7, 140453134: 140453134
43 BRAF NM_004333.4(BRAF): c.1801A> G (p.Lys601Glu) single nucleotide variant Pathogenic rs121913364 GRCh38 Chromosome 7, 140753334: 140753334
44 BRAF NM_004333.4(BRAF): c.1790T> G (p.Leu597Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913366 GRCh37 Chromosome 7, 140453145: 140453145
45 BRAF NM_004333.4(BRAF): c.1790T> G (p.Leu597Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913366 GRCh38 Chromosome 7, 140753345: 140753345
46 BRAF NM_004333.4(BRAF): c.1405G> C (p.Gly469Arg) single nucleotide variant Pathogenic rs121913357 GRCh37 Chromosome 7, 140481403: 140481403
47 BRAF NM_004333.4(BRAF): c.1405G> C (p.Gly469Arg) single nucleotide variant Pathogenic rs121913357 GRCh38 Chromosome 7, 140781603: 140781603
48 BRAF NM_004333.4(BRAF): c.1406G> C (p.Gly469Ala) single nucleotide variant Pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
49 BRAF NM_004333.4(BRAF): c.1406G> C (p.Gly469Ala) single nucleotide variant Pathogenic rs121913355 GRCh38 Chromosome 7, 140781602: 140781602
50 BRAF NM_004333.5(BRAF): c.1406G> A (p.Gly469Glu) single nucleotide variant Pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
Sources

Expression for Suppression of Tumorigenicity 12

About this section
Search GEO for disease gene expression data for Suppression of Tumorigenicity 12.
Sources

Pathways for Suppression of Tumorigenicity 12

About this section

Pathways related to Suppression of Tumorigenicity 12 according to GeneCards Suite gene sharing:

(show top 50) (show all 93)
# Super pathways Score Top Affiliating Genes
1
Human cytomegalovirus infection 37
Show member pathways
 13.13 AKT1 CTNNB1 HRAS PIK3CA PTEN SMAD4
2
PI3K-Akt signaling pathway 37
Show member pathways
 13.07 AKT1 CTNNB1 HRAS PIK3CA PTEN TP53
3
TNFR1 Pathway 64
Show member pathways
 13.02 AKT1 CTNNB1 HRAS PIK3CA PTEN TP53
4
Focal Adhesion 1 37
Show member pathways
 12.97 AKT1 BRAF CTNNB1 HRAS PIK3CA PTEN
5
Beta-Adrenergic Signaling 64
Show member pathways
 12.86 AKT1 BRAF CTNNB1 HRAS KLK3
6
Glioma 37
Show member pathways
 12.85 AKT1 BRAF HRAS PIK3CA PTEN TP53
7
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 65
Show member pathways
 12.84 AKT1 BRAF HRAS PIK3CA PTEN
8
Ras signaling pathway 37
Show member pathways
 12.79 AKT1 BRAF CTNNB1 HRAS PIK3CA
9
Downstream signaling events of B Cell Receptor (BCR) 66
Show member pathways
 12.79 AKT1 HRAS PIK3CA PTEN TP53
10
Development HGF signaling pathway 22
Show member pathways
 12.76 AKT1 BRAF CTNNB1 HRAS PIK3CA PTEN
11
Gastric cancer 37
Show member pathways
 12.75 AKT1 BRAF CTNNB1 GSTP1 HRAS PIK3CA
12
Development Endothelin-1/EDNRA signaling 22
Show member pathways
 12.74 AKT1 CTNNB1 HRAS PIK3CA PTEN
13
Immune response IL-23 signaling pathway 22
Show member pathways
 12.67 AKT1 CTNNB1 HRAS PIK3CA TP53
14
MicroRNAs in cancer 37
12.6 HRAS PIK3CA PTEN SLC45A3 TP53
15
mTOR signaling pathway (KEGG) 65
Show member pathways
 12.58 AKT1 BRAF HRAS PIK3CA PTEN TP53
16
Development EGFR signaling pathway 22
Show member pathways
 12.57 AKT1 BRAF CTNNB1 HRAS PIK3CA SMAD4
17
ErbB signaling pathway 1 37
Show member pathways
 12.56 AKT1 BRAF HRAS PIK3CA TP53
18
Apoptosis Pathway 72
Show member pathways
 12.52 AKT1 CTNNB1 HRAS PIK3CA TP53
19
Human T-cell leukemia virus 1 infection 37
12.49 AKT1 CTNNB1 HRAS PIK3CA SMAD4 TP53
20
AMP-activated Protein Kinase (AMPK) Signaling 1
Show member pathways
 12.48 AKT1 HRAS PIK3CA TP53
21
Development VEGF signaling via VEGFR2 - generic cascades 22
Show member pathways
 12.48 AKT1 BRAF CTNNB1 HRAS PIK3CA
22
Development IGF-1 receptor signaling 22
Show member pathways
 12.47 AKT1 HRAS PIK3CA PTEN TP53
23
B cell receptor signaling pathway (KEGG) 37
Show member pathways
 12.46 AKT1 BRAF HRAS PIK3CA PTEN
24
Pathways in cancer 37
12.45 AKT1 AR BRAF CTNNB1 GSTP1 HRAS
25
Oocyte meiosis 37
Show member pathways
 12.41 AKT1 AR BRAF PIK3CA
26
Development A3 receptor signaling 22
Show member pathways
 12.39 AKT1 CTNNB1 HRAS PIK3CA
27
B Cell Receptor Signaling Pathway (sino) 67
Show member pathways
 12.39 AKT1 HRAS PIK3CA PTEN
28
Toll Comparative Pathway 64
Show member pathways
 12.36 AKT1 HRAS PIK3CA TP53
29
Proteoglycans in cancer 37
12.33 AKT1 BRAF CTNNB1 HRAS PIK3CA TP53
30
G-protein signaling Ras family GTPases in kinase cascades (scheme) 22
Show member pathways
 12.32 AKT1 BRAF HRAS TP53
31
Colorectal Cancer Metastasis 64
12.27 AKT1 BRAF CTNNB1 SMAD4 TP53
32
MAPK Signaling: Mitogen Stimulation Pathway 65
Show member pathways
 12.27 AKT1 BRAF HRAS PIK3CA PTEN TP53
33
EGF/EGFR Signaling Pathway 1
12.26 AKT1 BRAF HRAS PTEN
34
Cellular senescence (KEGG) 37
12.26 AKT1 HRAS PIK3CA PTEN TP53
35
mTOR Pathway 72
Show member pathways
 12.26 AKT1 BRAF HRAS PIK3CA TP53
36
Kit receptor signaling pathway 1
Show member pathways
 12.25 AKT1 HRAS PIK3CA PTEN
37
NGF Pathway 64
Show member pathways
 12.22 AKT1 BRAF HRAS TP53
38
AKT Signaling Pathway 67
12.22 AKT1 HRAS PIK3CA PTEN TP53
39
Development EGFR signaling via small GTPases 22
Show member pathways
 12.21 AKT1 HRAS PIK3CA PTEN
40
Longevity regulating pathway 37
Show member pathways
 12.21 AKT1 HRAS PIK3CA TP53
41
Endometrial cancer 37
Show member pathways
 12.18 AKT1 AR BRAF CTNNB1 GSTP1 HRAS
42
Fluid shear stress and atherosclerosis 37
12.17 AKT1 CTNNB1 GSTP1 PIK3CA TP53
43
Signaling pathways regulating pluripotency of stem cells 37
12.17 AKT1 CTNNB1 HRAS PIK3CA SMAD4
44
TGF-beta Signaling Pathway (WikiPathways) 1
12.15 AKT1 KLF6 SMAD4 TP53
45
Hepatitis C 37
12.14 AKT1 BRAF HRAS PIK3CA TP53
46
Integrated Breast Cancer Pathway 1
12.14 AKT1 AR BRAF CTNNB1 PTEN SMAD4
47
Autophagy - animal 37
12.13 AKT1 HRAS PIK3CA PTEN
48
MAPK Pathway 72
Show member pathways
 12.11 AKT1 BRAF PIK3CA TP53
49
Development A2A receptor signaling 22
Show member pathways
 12.11 AKT1 BRAF CTNNB1 HRAS PIK3CA
50
FoxO signaling pathway 37
Show member pathways
 12.11 AKT1 BRAF HRAS PIK3CA PTEN SMAD4
Sources

GO Terms for Suppression of Tumorigenicity 12

About this section

Cellular components related to Suppression of Tumorigenicity 12 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.44 AKT1 AMACR AR BRAF CTNNB1 GSTP1

Biological processes related to Suppression of Tumorigenicity 12 according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.97 AKT1 BRAF CTNNB1 GSTP1 PTEN TP53
2 positive regulation of transcription by RNA polymerase II GO:0045944 9.97 AKT1 AR CTNNB1 HRAS KLF6 NKX3-1
3 protein deubiquitination GO:0016579 9.93 AR PTEN SMAD4 TP53
4 negative regulation of gene expression GO:0010629 9.93 AKT1 CTNNB1 HRAS NKX3-1
5 positive regulation of cell proliferation GO:0008284 9.93 AKT1 AR CTNNB1 HRAS NKX3-1 PTEN
6 positive regulation of transcription, DNA-templated GO:0045893 9.87 AKT1 AR CTNNB1 KLF6 NKX3-1 SMAD4
7 negative regulation of cell proliferation GO:0008285 9.8 AR CTNNB1 HRAS NKX3-1 PTEN SMAD4
8 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.79 AKT1 BRAF PIK3CA
9 negative regulation of ERK1 and ERK2 cascade GO:0070373 9.77 GSTP1 PTEN SMAD4
10 cellular response to drug GO:0035690 9.76 BRAF NKX3-1 TP53
11 negative regulation of epithelial cell proliferation GO:0050680 9.75 AR NKX3-1 PTEN
12 negative regulation of neuron death GO:1901215 9.72 AKT1 CHGA CTNNB1
13 androgen receptor signaling pathway GO:0030521 9.71 AR CTNNB1 NKX3-1
14 cellular response to hypoxia GO:0071456 9.71 AKT1 NKX3-1 PTEN TP53
15 cellular response to nerve growth factor stimulus GO:1990090 9.65 AKT1 BRAF PTEN
16 cellular response to steroid hormone stimulus GO:0071383 9.64 AR NKX3-1
17 seminiferous tubule development GO:0072520 9.62 AR SMAD4
18 anoikis GO:0043276 9.61 AKT1 PIK3CA
19 negative regulation of cell size GO:0045792 9.61 AKT1 PTEN
20 positive regulation of glucose metabolic process GO:0010907 9.6 AKT1 SLC45A3
21 prostate gland growth GO:0060736 9.57 AR PTEN
22 regulation of axon regeneration GO:0048679 9.56 BRAF PTEN
23 cellular response to decreased oxygen levels GO:0036294 9.52 AKT1 PTEN
24 epithelial cell differentiation involved in prostate gland development GO:0060742 9.51 AR CTNNB1
25 cell proliferation GO:0008283 9.5 AKT1 AR CTNNB1 HRAS PTEN SMAD4
26 protein kinase B signaling GO:0043491 9.46 AKT1 NKX3-1 PIK3CA PTEN
27 positive regulation of epithelial cell proliferation involved in prostate gland development GO:0060769 9.43 AR CTNNB1
28 positive regulation of gene expression GO:0010628 9.23 AKT1 AR BRAF CTNNB1 HRAS NKX3-1

Molecular functions related to Suppression of Tumorigenicity 12 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.72 AR KLF6 NKX3-1 SMAD4 TP53
2 transcription regulatory region DNA binding GO:0044212 9.67 AR NKX3-1 SMAD4 TP53
3 protein kinase binding GO:0019901 9.65 AKT1 CTNNB1 GSTP1 PTEN TP53
4 enzyme binding GO:0019899 9.55 AKT1 AR CTNNB1 PTEN TP53
5 I-SMAD binding GO:0070411 9.4 CTNNB1 SMAD4
6 androgen receptor activity GO:0004882 8.96 AR NKX3-1
7 RNA polymerase II transcription factor binding GO:0001085 8.92 AR CTNNB1 SMAD4 TP53
Sources

Sources for Suppression of Tumorigenicity 12

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....